
House Committee Passes IST Requirements in Chemical Facility Security Bill
The House Energy and Commerce Committee approved H.R. 2868, the "Chemical Facility Anti-Terrorism Act of 2009," a measure to modify and codify existing requirements of the Chemical Facility Anti-Terrorism Standards (CFATS) program.
The House Energy and Commerce Committee approved
Under the CFATS program, US chemical facilities are required to prepare security vulnerability assessments, which identify facility security vulnerabilities, and to develop and implement site-security plans, which include measures that satisfy the identified risk-based performance standards. The IST provisions in the House bill would add a requirement to existing industry security standards to mandate process or chemical substitution of certain chemicals as directed by the DHS Secretary. The IST provisions are supported by certain members of Congress but are opposed by the fine-chemical and chemical industries.
“This legislation requires for the first time that covered chemical facilities must assess whether there are any safer chemicals, processes, or technologies that they can adopt which would reduce the consequences of a terrorist attack against the facility,” said House Energy and Commerce Committee Chairman Henry Waxman (D-CA) in a
The Society of Chemical Manufacturers and Affiliates (SOCMA), the US-based trade association of batch and custom manufacturers, which include contract manufacturers of active pharmaceutical ingredients and intermediates, voiced its opposition to the IST provisions. In a
SOCMA argues that inherent safety cannot be measured and should not be mandated. In the letter to the committee, SOCMA said, “Even if measuring the effectiveness of IST was possible, the provision takes the decision about risk away from the workers in chemical facilities and leaves them to bureaucrats in Washington.” Instead of adopting IST, SOCMA is urging Congress to extend the existing CFATS program.
The American Chemistry Council (ACC), which represents the large US chemical manufacturers, also raised concerns over the mandated IST provisions although it reiterated its overall support for chemical-facility security and the CFATS program. “We are still unable to find common ground with the committee on the right approach regarding the regulation of process changes and product substitutions,” said Calvin Dooley, president and CEO of the ACC, in an
The bill has been placed on the House calendar for further consideration.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.





